W
VRTX icon

WealthStone’s Vertex Pharmaceuticals VRTX Stock Holding History

WealthStone’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$250K Buy
1,167
+142
+14% +$31.2K 0.09% 201
2020
Q4 		$242K Sell
1,025
-57
-5% -$13.1K 0.09% 173
2020
Q3 		$294K Buy
+1,082
New +$299K 0.13% 110
2019
Q3 		– Sell
-2,575
Closed -$472K – 588
2019
Q2 		$472K Buy
+2,575
New +$450K 0.21% 86

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

WealthStone's VRTX Position: Q1 2021 in Review

WealthStone increased its Vertex Pharmaceuticals (VRTX) stake by 14% in Q1 2021, buying an estimated $31.2K and bringing the position to 1,167 shares worth $250K. The position accounts for 0.09% of the portfolio, ranked #201.

WealthStone first reported a position in VRTX in Q2 2019 and has held it in 4 quarters since. The position peaked at $472K in Q2 2019. 999 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

  • WealthStone held 1,167 shares of Vertex Pharmaceuticals worth $250K as of Q1 2021.
  • WealthStone bought 142 Vertex Pharmaceuticals shares in Q1 2021, an estimated $31.2K.
  • Vertex Pharmaceuticals made up 0.09% of WealthStone's portfolio in Q1 2021, its #201 holding.
  • WealthStone first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 4 quarters since.
  • WealthStone's Vertex Pharmaceuticals position peaked at $472K in Q2 2019.
  • 999 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on WealthStone's 13F filing for Q1 2021, filed 13 May 2021.